
High circulating galectin-3 is associated with poor outcomes in patients with coronavirus disease (COVID-19). Therefore, the authors hypothesized that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with antiinflammatory and antifibrotic actions, would be safely and effectively delivered in COVID-19 pneumonitis. Therefore, this study aims to evaluate the safety and tolerability of inhaled GB0139 as an add-on therapy for patients hospitalized with COVID-19 pneumonitis. Data are reported from 41 patients, 20 randomly assigned to receive GB0139. In COVID-19 pneumonitis, inhaled GB0139 was well-tolerated and achieved clinically relevant plasma concentrations with target engagement.
Like
Save
Share